Pan-cancer analysis of DNA methyltransferase family with potential implications in prognosis and immunology in human cancer  

作　　者：Jiayu Ding Hao Shen Dawei Wang Wenbin Kuang Liping Wang Xiao Wang Peng Yang 

机构地区：[1]State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Design and Optimization,China Pharmaceutical University,Nanjing,Jiangsu 210009,China [2]Department of Medicinal Chemistry,School of Pharmacy,China Pharmaceutical University,Nanjing,Jiangsu 211198,China

出　　处：《Genes & Diseases》2023年第4期1206-1209,共4页基因与疾病（英文）

基　　金：supported by National Natural Science Foundation of China(No.82073701,31900687);Natural Science Foundation of Jiangsu Province(China)(No.BK20190551);the Project Program of State Key Laboratory of Natural Medicines,China Pharmaceutical University(No.SKLNMZZ202013);supported by Jiangsu Key Laboratory of Drug Design and Optimization,China Pharmaceutical University(No.2020KFKT-5);“Double First-Class”University Project(China)(No.CPU2018GF04).

摘　　要：DNA methylation,as a key epigenetic modification affecting gene expression,is catalyzed by DNA methyl-transferase(DNMT).DNMT1,DNMT3A,and DNMT3B are the main members of the DNMT family,which have been found to regulate many biological processes.^(1)Aberrant DNA methylation in the promoter of tumor suppressor genes is considered a biomarker in cancer.However,no evidence of regulatory mechanisms and pathways relating to DNMTs and immune abnormalities has been provided.

关 键 词：CANCER SUPPRESSOR PROGNOSIS 

分 类 号：R73[医药卫生—肿瘤]